CLINICAL TRIALS PROFILE FOR ROCEPHIN KIT

All Clinical Trials for ROCEPHIN KIT

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00566111 ↗	Ceftriaxone in the Management of Bipolar Depression	Terminated	Stanley Medical Research Institute	N/A	2007-09-01	We aim to study the efficacy of intravenous ceftriaxone in a four-week, inpatient, placebo-controlled, double-blind study, as an augmentation therapy in patients with bipolar disorder, currently depressed, who have failed to respond to conventional treatments.
NCT00566111 ↗	Ceftriaxone in the Management of Bipolar Depression	Terminated	Yale University	N/A	2007-09-01	We aim to study the efficacy of intravenous ceftriaxone in a four-week, inpatient, placebo-controlled, double-blind study, as an augmentation therapy in patients with bipolar disorder, currently depressed, who have failed to respond to conventional treatments.
NCT00540072 ↗	Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia Due to S. Pneumoniae	Completed	Cubist Pharmaceuticals LLC	Phase 3	2001-07-30	A COMPARASON OF CIDECIN™ (DAPTOMYCIN) TO ROCEPHIN® (CEFTRIAXONE) IN THE TREATMENT OF MODERATE TO SEVERE COMMUNITY-ACQUIRED ACUTE BACTERIAL PNEUMONIA DUE TO S. PNEUMONIAE
NCT00035347 ↗	Intravenous Azithromycin Plus Intravenous Ceftriaxone Followed by Oral Azithromycin With Intravenous Levofloxacin Followed by Oral Levofloxacin for the Treatment of Moderate to Severely Ill Hospitalized Patients With Community Acquired Pneumonia	Completed	Pfizer	Phase 4	2001-01-01	A trial in which patients over 18 years of age who are hospitalized with community acquired pneumonia and are otherwise eligible for entry into the study are randomly selected to receive one of two treatment regimens. After written informed consent is obtained, patients will receive one of the following two treatment regimens: 1) intravenous administration of azithromycin and ceftriaxone followed by azithromycin tablets, or 2) intravenous administration of levofloxacin followed by levofloxacin tablets. At least four study visits are normally conducted up to approximately one month after starting therapy. The objective of this study is to compare the safety and efficacy of the two treatment regimens.
NCT00538694 ↗	Comparative Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia	Completed	Cubist Pharmaceuticals LLC	Phase 3	2000-10-31	To evaluate the safety and efficacy of daptomycin in adults who have pneumonia due to Streptococcus pneumoniae.
NCT00037479 ↗	Brain Imaging and Retreatment Study of Persistent Lyme Disease	Completed	National Institute of Neurological Disorders and Stroke (NINDS)	Phase 2	1999-12-01	The purpose of this study is to determine whether patients with persistent memory problems after Lyme disease benefit from an additional longer course of IV antibiotic therapy; to use modern brain imaging technology to determine whether the problem in the central nervous system is primarily one of poor blood flow or one of impaired nerve cell functioning; and to try to identify biological markers prior to treatment that will identify patients who are more or less likely to respond to the study treatment.

Clinical Trial Conditions for ROCEPHIN KIT

Condition Name

Condition Name for ROCEPHIN KIT
Intervention	Trials
Pneumonia, Bacterial	2
Cirrhosis, Liver	1
Intra-abdominal Infections	1
Post-Op Wound Infection	1

Condition MeSH

Condition MeSH for ROCEPHIN KIT
Intervention	Trials
Infections	3
Infection	3
Pneumonia	3
Pneumonia, Bacterial	2

Clinical Trial Locations for ROCEPHIN KIT

Trials by Country

+

−

Trials by Country for ROCEPHIN KIT
Location	Trials
United States	21
Japan	15
Canada	6
Taiwan	3
France	2

Trials by US State

+

−

Trials by US State for ROCEPHIN KIT
Location	Trials
Pennsylvania	2
Ohio	2
New York	2
Michigan	2
California	2

Clinical Trial Progress for ROCEPHIN KIT

Clinical Trial Phase

Clinical Trial Phase for ROCEPHIN KIT
Clinical Trial Phase	Trials
Phase 4	8
Phase 3	4
Phase 2	6

Clinical Trial Status

Clinical Trial Status for ROCEPHIN KIT
Clinical Trial Phase	Trials
Completed	9
Unknown status	4
Recruiting	3

Clinical Trial Sponsors for ROCEPHIN KIT

Sponsor Name

Sponsor Name for ROCEPHIN KIT
Sponsor	Trials
Pfizer	3
Cubist Pharmaceuticals LLC	2
Stanley Medical Research Institute	1

Sponsor Type

Sponsor Type for ROCEPHIN KIT
Sponsor	Trials
Other	35
Industry	7
NIH	2

Clinical Trials, Market Analysis, and Projections for Ceftriaxone (ROCEPHIN)

Introduction to Ceftriaxone (ROCEPHIN)

Ceftriaxone, marketed under the brand name ROCEPHIN, is a broad-spectrum cephalosporin antibiotic used to treat a variety of bacterial infections. It is administered intravenously or intramuscularly and is known for its efficacy in treating infections such as pneumonia, urinary tract infections, and skin and skin structure infections.

Clinical Trials and Efficacy

Current Clinical Use

Ceftriaxone is widely used in clinical settings for its broad spectrum of activity against Gram-positive and Gram-negative bacteria. It is particularly effective in treating multi-drug resistant infections, which is a significant driver of its market growth[2].

Comparative Studies

In the context of treating uncomplicated urogenital gonorrhoea, ceftriaxone is often used in combination with azithromycin. Recent trials, such as the EAGLE-1 phase III trial, have compared the efficacy of this combination with new antibiotics like gepotidacin. The EAGLE-1 trial demonstrated that gepotidacin was non-inferior to the ceftriaxone plus azithromycin combination, highlighting the ongoing need for new treatment options due to rising antibiotic resistance[1].

Market Analysis

Market Size and Growth

The global ceftriaxone market is expected to grow at a compound annual growth rate (CAGR) of 2.9% to 3.1% from 2022 to 2032. In 2021, the market size was valued at approximately $1.7 billion and is projected to exceed $2.2 billion by 2031[2][5].

Key Drivers

• Efficacy in Multi-Drug Resistant Infections: Ceftriaxone's effectiveness against a broad spectrum of bacteria, including those resistant to other antibiotics, is a major driver of its market growth[2].
• Rising Incidence of Bacterial Infections: The increasing burden of bacterial infections globally, particularly in regions like Asia-Pacific, is driving the demand for ceftriaxone[2][5].
• Generic and Branded Versions: The availability of both generic and branded versions of ceftriaxone, especially in parenteral formulations, is driving market growth. Generic versions offer cost-effective treatment options, particularly in developing countries[5].

Geographical Trends

• Asia-Pacific: This region is expected to witness the highest CAGR due to the increasing burden of bacterial infections and improving healthcare infrastructure. Countries like China and India are seeing a significant rise in demand for ceftriaxone[2][5].
• North America: This region is anticipated to maintain its position as the highest revenue-generating market, driven by robust healthcare systems and a high prevalence of bacterial infections[2].

Competitive Landscape

The ceftriaxone market is characterized by several key players, including Pfizer, Roche, Novartis, Hikma Pharmaceuticals plc, Qilu Pharmaceutical Co. Ltd., Baxter International, Inc., Aurobindo Pharma, and others. These companies are investing heavily in research and development to address the global challenge of antibiotic resistance and to explore new therapeutic applications[2].

Challenges and Opportunities

Antibiotic Resistance

One of the significant challenges facing the ceftriaxone market is the growing concern of antibiotic resistance. As bacteria become more resistant to existing antibiotics, there is a pressing need for new and effective treatments. This challenge also presents an opportunity for pharmaceutical companies to develop new antibiotics and treatment regimens[1][2].

Regulatory and Stewardship Issues

Antibiotic stewardship programs and regulatory oversight are crucial in ensuring the continued efficacy of ceftriaxone. Companies must navigate these challenges while maintaining their market presence and addressing evolving healthcare needs[2].

Future Projections

Market Forecast

The ceftriaxone market is expected to continue growing, driven by its efficacy in treating multi-drug resistant infections and the rising incidence of bacterial infections. The Asia-Pacific region is likely to be a key growth area due to its large patient pool and improving healthcare infrastructure[2][5].

New Therapeutic Applications

Companies like Roche and Novartis are exploring new therapeutic applications for ceftriaxone, which could further expand its market potential. This includes investigating its use in different types of infections and developing new formulations to enhance patient compliance and treatment outcomes[2].

Conclusion

Ceftriaxone remains a critical antibiotic in the treatment of various bacterial infections. Its market is driven by its efficacy, the rising incidence of bacterial infections, and the availability of generic and branded versions. However, the challenge of antibiotic resistance necessitates ongoing research and development to ensure the continued efficacy of ceftriaxone and the development of new treatment options.

Key Takeaways

• Ceftriaxone is effective in treating multi-drug resistant infections.
• The global ceftriaxone market is expected to grow at a CAGR of 2.9% to 3.1% from 2022 to 2032.
• Asia-Pacific is expected to be a key growth region due to its large patient pool and improving healthcare infrastructure.
• Antibiotic resistance is a significant challenge that requires ongoing research and development.
• Generic and branded versions of ceftriaxone are driving market growth, especially in developing countries.

FAQs

What is the current market size of the ceftriaxone market?

The global ceftriaxone market was valued at approximately $1.7 billion in 2021[5].

What is the projected growth rate of the ceftriaxone market?

The ceftriaxone market is expected to grow at a CAGR of 2.9% to 3.1% from 2022 to 2032[2][5].

Which region is expected to witness the highest growth in the ceftriaxone market?

The Asia-Pacific region is expected to witness the highest CAGR due to the increasing burden of bacterial infections and improving healthcare infrastructure[2][5].

What are the key drivers of the ceftriaxone market?

Key drivers include its efficacy in treating multi-drug resistant infections, the rising incidence of bacterial infections, and the availability of generic and branded versions[2][5].

Who are the major players in the ceftriaxone market?

Major players include Pfizer, Roche, Novartis, Hikma Pharmaceuticals plc, Qilu Pharmaceutical Co. Ltd., and others[2].

Sources

1. GSK announces positive headline results from EAGLE-1 phase III trial for gepotidacin in uncomplicated urogenital gonorrhoea (GC) - GSK.
2. Ceftriaxone Industry Research 2024: Effective Treatment of Multi-Drug Resistant Infections Bolsters Growth Global Forecasts to 2032 - GlobeNewswire.
3. Clinical Trial Kits Market Size & Share Report 2021-2028 - Grand View Research.
4. ROCEPHIN (ceftriaxone sodium) FOR INJECTION Rx only - FDA.
5. Ceftriaxone Market Size, Share, and Forecast 2022–2031 - Transparency Market Research.